% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Goldschmidt:132475,
      author       = {H. Goldschmidt and H. M. Lokhorst and E. K. Mai and B. van
                      der Holt and I. W. Blau and S. Zweegman and K. C. Weisel and
                      E. Vellenga and M. Pfreundschuh and M. J. Kersten and C.
                      Scheid and S. Croockewit and R. Raymakers and D. Hose and A.
                      Potamianou and A. Jauch and J. Hillengass and M.
                      Stevens-Kroef and M. S. Raab and A. Broijl and H. W.
                      Lindemann and G. M. J. Bos and P. Brossart and M. van
                      Marwijk Kooy and P. Ypma and U. Duehrsen and R. M. Schaafsma
                      and U. Bertsch and T. Hielscher$^*$ and L. Jarari and H. J.
                      Salwender and P. Sonneveld},
      title        = {{B}ortezomib before and after high-dose therapy in myeloma:
                      long-term results from the phase {III}
                      {HOVON}-65/{GMMG}-{HD}4 trial.},
      journal      = {Leukemia},
      volume       = {32},
      number       = {2},
      issn         = {1476-5551},
      address      = {Basingstoke},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2018-00163},
      pages        = {383 - 390},
      year         = {2018},
      abstract     = {The Dutch-Belgian Cooperative Trial Group for Hematology
                      Oncology Group-65/German-speaking Myeloma Multicenter
                      Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared
                      bortezomib (BTZ) before and after high-dose melphalan and
                      autologous stem cell transplantation (HDM, PAD arm) compared
                      with classical cytotoxic agents prior and thalidomide after
                      HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65
                      years. Here, the long-term follow-up and data on second
                      primary malignancies (SPM) are presented. After a median
                      follow-up of 96 months, progression-free survival (censored
                      at allogeneic transplantation, PFS) remained significantly
                      prolonged in the PAD versus VAD arm (hazard ratio (HR)=0.76,
                      $95\%$ confidence interval $(95\%$ CI) of 0.65-0.89,
                      P=0.001). Overall survival (OS) was similar in the PAD
                      versus VAD arm (HR=0.89, $95\%$ CI: 0.74-1.08, P=0.24). The
                      incidence of SPM were similar between the two arms $(7\%$
                      each, P=0.73). The negative prognostic effects of the
                      cytogenetic aberration deletion 17p13 (clone size $⩾10\%)$
                      and renal impairment at baseline (serum creatinine
                      >2 mg dl-1) on PFS and OS remained abrogated in the PAD
                      but not VAD arm. OS from first relapse/progression was
                      similar between the study arms (HR=1.02, P=0.85). In
                      conclusion, the survival benefit with BTZ
                      induction/maintenance compared with classical cytotoxic
                      agents and thalidomide maintenance is maintained without an
                      increased risk of SPM.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28761118},
      doi          = {10.1038/leu.2017.211},
      url          = {https://inrepo02.dkfz.de/record/132475},
}